Esteve Invests €71 Million to Relocate and Expand China Factory

✦ Meridian Analysis

Esteve has signed a €71 million investment to relocate and expand its active‑pharmaceutical‑ingredient (API) manufacturing plant in China. The move aims to strengthen its industrial capacity for manufacturing active pharmaceutical ingredients for third parties. The transaction is at the signed stage. Deal professionals will be watching for details on the financing package – the size and composition of senior and mezzanine tranches, interest rates, and any covenants tied to production milestones – as well as the identities of the banks or institutional lenders involved. Information on the expected completion date, local regulatory clearances and any off‑take agreements with third‑party customers has not been disclosed.

The Meridian Weekly